Comparative Pharmacology
Head-to-head clinical analysis: ERTAPENEM SODIUM versus PRIMAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERTAPENEM SODIUM versus PRIMAXIN.
ERTAPENEM SODIUM vs PRIMAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ertapenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death. It is a carbapenem antibiotic with broad-spectrum activity against Gram-positive and Gram-negative aerobes and anaerobes.
Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death. Cilastatin prevents renal metabolism of imipenem by inhibiting dehydropeptidase I.
1 g IV or IM once daily.
1 g (imipenem 500 mg + cilastatin 500 mg) IV every 6 hours for adults with normal renal function. Maximum 4 g/day.
None Documented
None Documented
Terminal half-life: ~4 hours (range 3.5-5.3) in young adults; prolonged in renal impairment (e.g., ~7.5 hours in moderate impairment, ~13 hours in end-stage renal disease)
Terminal elimination half-life: 1 hour. In patients with impaired renal function, half-life extends up to 4-6 hours in moderate impairment and >10 hours in severe impairment.
Renal: ~80% unchanged in urine; fecal: ~10% as metabolites; biliary: minimal (<1%)
Renal (approximately 70% as unchanged drug via glomerular filtration and tubular secretion) and 20-30% biliary/fecal.
Category A/B
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic